The treatment of neuroleptic malignant syndrome using dantrolene sodium

Psychiatry and Clinical Neurosciences

Volumn 52, Issue 4, 1998, Pages 433-438

  Tsutsumi, Yasuhiko ^a   Yamamoto, Kenji ^b   Matsuura, Shinsuke ^b   Hata, Shunji ^c   Sakai, Masao ^a   Shirakura, Katsuyuki ^d  

^a Kinkoh Hospital   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c Totsuka Animal Hospital   (Japan)

^d KURIHAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Dantrolene sodium; Dosage; Duration; Neuroleptic malignant syndrome; Treatment

Indexed keywords

BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROMAZINE; CREATINE KINASE; DANTROLENE; LITHIUM CARBONATE; MAPROTILINE; NEUROLEPTIC AGENT; OXYPERTINE; THIORIDAZINE; ZOTEPINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; NEUROLEPTIC MALIGNANT SYNDROME; PROGNOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CONSCIOUSNESS; DANTROLENE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031713118     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.1998.00416.x     Document Type: Article

References (28)

1. Delay J, Pichot P, Lemperiere T. Un neuroleptique majeur non phenothiazinique et non reserpinique, l'haloperidol dans le treatement des psychoses. Ann. Med. Psychol. 1960; 118: 145-152 (in French).
2. Delay J, Deniker P. Drug-induced extrapyramidal syndromes. In: Vinken PJ (ed.) Handbook of Clinical Neurology. Elsevier North Holland Inc., New York, 1968; 6: 248-266.
3. Caroff SN. The neuroleptic malignant syndrome. J. Clin. Psychiatry 1980; 41: 79-83.
4. Cohen BM, Baldessarini R, Pope HG. Neuroleptic malignant syndrome. N. Engl. J. Med. 1985; 313: 1293.
5. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptom with fever. Heterogeneity of the 'neuroleptic malignant syndrome'. Arch. Gen. Psychiatry 1986; 43: 839-848.
6. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J. Clin. Psychiatry 1989; 50: 18-25.
7. Yano E, Yamawaki S. Epidemiology of neuroleptic malignant syndrome in Japan. Jpn J. Clin. Psychiatry 1989; 18: 465-471 (in Japanese).
8. Tsutsumi Y, Yamamoto K, Hata S, Sakai M, Shirakura K. Incidence of 'typical cases' and 'incomplete cases' of neuroleptic malignant syndrome and their epidemiological study. Jpn J. Psychiatry Neurol. 1994; 48: 789-799.
9. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry 1986; 143: 1227-1233.
10. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol. Psychiatry 1987; 22: 1004-1020.
11. Coons DJ, Hillman FJ, Marshall RW. Treatment of neuroleptic malignant syndrome with dantrolene sodium: A case report. Am. J. Psychiatry 1982; 139: 944-945.
12. Goekoop JG, Carbatt PA. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 1982; 3: 49-50.
13. Granato JE, Stern BJ, Ringel A et al. Neuroleptic malignant syndrome: Successful treatment with dantrolene and bromocriptine. Ann. Neurol. 1983; 14: 89-90.
14. Yamawaki S, Yano E, Kobayashi R et al. A survey on neuroleptic malignant syndrome in Japan. From the study of Japanese research group of neuroleptic malignant syndrome. Jpn J. Clin. Psychiatry 1989; 18: 107-121 (in Japanese).
15. Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch. Intern. Med. 1989; 149: 1927-1931.
16. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br. J. Psychiatry 1991; 159: 709-712.
17. Olmsted TR. Neuroleptic malignant syndrome: Guidelines for treatment and reinstitution of neuroleptics. South. Med. J. 1988; 81: 888-891.
18. Tajima O, Sekikawa A. Guidelines for treatment of neuroleptic malignant syndrome: Specific treatment with bromocriptine and dantrolene. Jpn J. Psychiatr. Treat. 1989; 4: 973-984 (in Japanese).
19. Sudoh K, Kobayashi Y, Suganuma Y, Yamashita K, Ikeda T. Six suspected cases of syndrome malin: Clinical effects of intravenous and oral administration of dantrolene sodium. Jpn J. Clin. Psychiatry 1985; 14: 249-260 (in Japanese).
20. Kikumoto O, Kawai K, Yokota N et al. A study of clinical treatment for neuroleptic malignant syndrome. Seishin Igaku. 1993; 35: 507-513 (in Japanese).
21. Yamawaki S, Morio M, Kazamatsuri G et al. Clinical evaluation and effective usage of dantrolene sodium on neuroleptic malignant syndrome. Kiso to Rinsyou. 1993; 27: 1045-1066 (in Japanese).
22. Levenson JL. Neuroleptic malignant syndrome. Am. J. Psychiatry 1985; 142: 1137-1145.
23. May DC, Morris SW, Stewart RM, Fenton DJ, Gaffney FA. Neuroleptic malignant syndrome: Response to dantrolene sodium. Ann. Intern. Med. 1983; 98: 183-184.
24. Yamawaki S, Hotta I, Uchitomi Y et al. Central effect of dantrolene: Effect on intracellular Ca metabolism related to 5-HT release in hypothalamus. Hiroshima J. Anesth. 1987; 23: 159-163 (in Japanese).
25. Ward A, Chaffman MO, Sorkin EM. Dantrolene: A review of its pharmacodynamic and properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32: 130-168.
26. Andrade NN. Emergency treatment of neuroleptic malignant syndrome. Hawaii Med. J. 1988; 47: 181-185.
27. Wells AJ, Sommi RW, Crismon ML. Neuroleptic rechallenge after neuroleptic malignant syndrome: Case report and literature review. Drug Intell. Clin. Pharm. 1988; 22: 475-480.
28. Shalev A, Munitz H. The neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiatr. Scand. 1986; 73: 337-347.